In a survey fielded in July and August of 2021, ZS again queried 1,250 key pharma stakeholders to take the pulse of the healthcare landscape another year into the COVID-19 pandemic. This research, which involved a 15-minute online survey, was a follow up to last year’s study into patient and physician perspectives on care delivery, telemedicine, vaccinations and pharma’s role in the pandemic.
Respondents completed their surveys as vaccination rates plateaued, patients returned to largely in-person office visits and worries about COVID-19 variants clouded the resumption of day-to-day life. Our research revealed definite signs of recovery, though most don’t expect a “new normal” to arrive until Q3 of 2022. We also found that there are immediate opportunities for pharma to support healthcare providers and patients. See the infographic below for highlights.